Hemodynamics, fluids & transfusion
Exploring the orepinephrine to ngiotensin II onversion atio in atients with asodilatory ypotension: A ost-oc nalysis of the ARAMIS rial
Authors' conclusion
The norepinephrine to angiotensin II conversion dose ratio is 10:1 in a vasodilatory hypotension population.
Study context
- Population
- Patients with vasodilatory hypotension in the ARAMIS trial
- Participants
- 37 patients
- Comparison
- High renin vs Low renin vs ARB vs Non-ARB
- Primary endpoint
- Conversion dose ratio between norepinephrine equivalent dose immediately prior to angiotensin II initiation and angiotensin II
Methodological detailssubgroup analyses
- Subgroup analyses
Primary result
As reported in the abstract
Norepinephrine to angiotensin II conversion dose ratio
Median conversion dose ratio, norepinephrine bitartrate
10:1
Median conversion dose ratio, norepinephrine base
5:1
Further findings
Median
| Outcome | High renin | Low renin | ARB | Non-ARB |
|---|---|---|---|---|
| Conversion ratio by baseline renin (subgroup) | 10 (IQR 7–21) | 12 (IQR 5–22) | — not stated in the abstract | — not stated in the abstract |
| Conversion ratio by prior ARB exposure (subgroup) | — not stated in the abstract | — not stated in the abstract | 7 (IQR 4–13) | 12 (IQR 7–22) |
— not stated in the abstract
Conversion ratio by baseline renin (subgroup)
- Conversion ratio not affected by baseline renin
Conversion ratio by prior ARB exposure (subgroup)
- ARB exposure prior admission appeared to diminish the conversion ratio
Original publication
Exploring the orepinephrine to ngiotensin II onversion atio in atients with asodilatory ypotension: A ost-oc nalysis of the ARAMIS rial. J Crit Care. Published 26 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →